Long-Term Tolerability and Safety of AAV5 -Id3 Gene Therapy to Eyes

Key Points

• AAV5-Id3 gene therapy effectively treats corneal fibrosis without significant side effects.
• Topical application of the therapy shows promising results in vivo for managing ocular conditions.
• The analysis highlights the long-term tolerability of AAV5-Id3 in corneal treatments, indicating its potential.
• Further studies may validate these findings and explore broader implications in eye therapy.

Abstract